AE adds two new trials to its Clinical Trials Watch

14/06/2022

Alzheimer Europe continues to develop and improve its Clinical Trials Watch (CTW), an innovative online resource providing up-to-date accessible information on clinical trials currently recruiting participants in a least one European country. The service provides information on phase II and III clinical trials that are investigating drugs for the prevention and treatment of dementia and/or Alzheimer’s disease (AD).

Two new trials have recently been added to the service:

• ROMEMA Phase II trial validating whether chronic intake roflumilast can improve cognition in people with (amnestic) mild cognitive impairment and in people with mild dementia (Maastricht University Medical Center)

• SKYLINE Phase III trial evaluating gantenerumab in cognitively unimpaired people with the earliest biological signs of AD (Roche).

Further information about the CTW is available on: https://www.alzheimer-europe.org/research/clinical-trials